A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and MultipleAscending Dose Study of AMG 133 in Subjects with Obesity

Background: Incretin-based therapeutics have been shown to improve glucose homeostasis, promote weight loss, and improve cardiovascular outcomes. AMG 133 is a glucose-dependent insulinotropic polypeptide antagonist antibody conjugated to analog peptides of glucagon-like peptide-1. This Phase 1, first-in-human study was designed to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamic effects in subjects with obesity and without diabetes.